Studies: Benralizumab not effective reducing exacerbations in moderate to very severe COPD

New research published online May 20, 2019 by the New England Journal of Medicine and co-led by Temple’s Gerard J. Criner, M.D., FACP, FACCP shows that the asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, a history of frequent moderate and/or severe exacerbations, and eosinophilic inflammation.
Source: EurekaAlert, https://www.eurekalert.org